NASDAQ:MRNA
Moderna, Inc.
Moderna, Inc.'s revenue fell 39.9% in fiscal 2025 to $1.9B while operating margin fell to −158.1%. Free cash flow was −$2.1B, −106.2% of revenue, and the diluted share count rose 1.3%.Summary generated from Moderna, Inc.'s SEC filings. Latest annual report filed Feb 20, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.9B
Revenue growth−39.9%
Revenue, 5-yr CAGR+19.3%
Gross margin55.3%
Operating margin−158.1%
Net margin−145.2%
ROIC−31.1%
Return on equity−28.9%
Debt / equity0.07
Free cash flow−$2.1B
FCF margin−106.2%
Share count change+1.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 18,471 | 19,263 | 6,848 | 3,236 | 1,944 |
| Operating income | 13,296 | 9,420 | −4,239 | −3,945 | −3,074 |
| Net income | 12,202 | 8,362 | −4,714 | −3,561 | −2,822 |
| Free cash flow | 13,336 | 4,581 | −3,825 | −4,055 | −2,065 |
Recent filings
- 4Insider transaction report
Oct 7, 2026 - 8-KDirector or officer change
Sep 30, 2026 - 4Insider transaction report
Sep 16, 2026 - 8-KEntry into a material agreement
Sep 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 31, 2026 - 8-KResults of operations and financial condition
Jul 31, 2026 - 8-KDirector or officer change
Jul 8, 2026 - 8-KAmendment to articles or bylaws
May 11, 2026